Stock Ratings / Health Care / GMED / insiders

PODD (73) BAX (51) PEN (57) SOLV (45) ⌘ Pro Terminal →

Globus Medical Inc. (GMED) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$82.91 +2.03% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Globus Medical Inc. (GMED) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (67% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $11.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GMED)Realized 20D OHLCV Swing Band: ±5.9%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

GMED Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GMED)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GMED. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GMED Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 1,540+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GMED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.49%⚡ TESTING RESISTANCE

2026-11-01O $81.26H $82.91L $81.26C $82.91VOL 862.0K

RES: $83.21SUP: $72.21SMA50: $77.54SMA200: $83.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GMED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GMED Butterfly Map → + Track GMED →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.3%/yr Implied 5Y Growth

vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GMED today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GMED. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GMED today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GMED)

Health Care Rank #51 of 188 ⚔️ PODD vs GMED Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GMED vs. PODD, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (21 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Globus Medical Inc. (GMED) ranks #51 by composite RQD confidence (72/100, grade B) and #100 by equity capitalization ($11.13B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with GMED at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GMED ACTIVE Globus Medical Inc.	B	72/100	20.7x	67.4%	8.7%	+2.03%	$11.13B	Benchmark Subject
PODD Insulet Corporation	B	73/100	42.8x	71.6%	20.4%	+2.40%	$10.58B	/podd-vs-gmed →
BAX Baxter International Inc.	D	51/100	—	30.1%	-2.4%	-7.70%	$12.15B	/bax-vs-gmed →
PEN Penumbra Inc.	D+	57/100	71.4x	67.1%	10.6%	+1.15%	$12.68B	/pen-vs-gmed →
SOLV Solventum Corporation	D	45/100	9.1x	53.5%	18.7%	+2.09%	$14.22B	/solv-vs-gmed →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001237831

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Globus Medical Inc. (GMED) reported GAAP revenue of $2.94B (+16.7% vs. FY2024 revenue of $2.52B , and +87.4% cumulative change since FY2023) , GAAP net income of $537.9M, operating cash flow of $753.4M, and free cash flow of $588.8M (+45.3% YoY). On the balance sheet, GMED closed FY2025 with $5.30B in total assets against $328.3M in total debt (Altman Z-Score: 10.74, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.94B	$537.9M	$753.4M	$588.8M	$5.30B	$328.3M
FY2024 (FY)	2024-12-31	$2.52B	$103.0M	$520.6M	$405.2M	$5.25B	$483.5M
FY2023 (FY)	2023-12-31	$1.57B	$122.9M	$243.5M	$172.9M	$6.12B	$1.43B

3. GMED Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Globus Medical Inc. (NYSE: GMED) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $82.91 (+2.03% 1D, market cap $11.13B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 188 tracked Health Care issuers, GMED ranks #51 in composite RQD confidence.

How does GMED compare to PODD and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable B (72/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (73/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.58B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GMED?

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GMED trading relative to its 50-day, 200-day, and 52-week technical levels?

GMED last traded at $82.91 (+2.03% on volume of 862,024 shares), positioning the stock +6.93% above its 50-day simple moving average ($77.54) and -0.64% below its 200-day simple moving average ($83.44). Across its 52-week range of $59.51 to $101.40, GMED sits at the 55.9% percentile with a 14-day RSI of 59.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.9% ($78.02 to $87.80).

GMED Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are GMED insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies GMED leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: GMED RQD Cockpit GMED 12M Forecast GMED Earnings & Move GMED Dividends & DRIP GMED Insiders & 13F GMED Whale Options GMED Profit Sankey GMED News & Why